KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Receivables - Accured (2022 - 2025)

Historic Revenue - Other for Arbutus Biopharma (ABUS) over the last 8 years, with Q2 2017 value amounting to $721000.0.

  • Arbutus Biopharma's Revenue - Other rose 16028.88% to $721000.0 in Q2 2017 from the same period last year, while for Jun 2017 it was $1.8 million, marking a year-over-year decrease of 8187.16%. This contributed to the annual value of $10.0 million for FY2017, which is 69381.93% up from last year.
  • According to the latest figures from Q3 2025, Arbutus Biopharma's Receivables - Accured is $300000.0, which was down 0.0% from $100000.0 recorded in Q2 2025.
  • Arbutus Biopharma's 5-year Receivables - Accured high stood at $600000.0 for Q4 2022, and its period low was $100000.0 during Q2 2025.
  • Its 4-year average for Receivables - Accured is $425000.0, with a median of $450000.0 in 2022.
  • In the last 5 years, Arbutus Biopharma's Revenue - Other crashed by 9979.92% in 2013 and then surged by 3910000.0% in 2014.
  • Quarter analysis of 5 years shows Arbutus Biopharma's Revenue - Other stood at $5.0 million in 2013, then crashed by 79.69% to $1.0 million in 2014, then surged by 705.67% to $8.2 million in 2015, then plummeted by 97.62% to $196000.0 in 2016, then skyrocketed by 267.86% to $721000.0 in 2017.
  • Its last three reported values are $721000.0 in Q2 2017, $217000.0 for Q1 2017, and $196000.0 during Q4 2016.